Clinical Efficacy And Safety Of Telbivudine And Entecavir In The Treatment Of Patients With E Antigen-Positive Chronic Hepatitis B

Objective To compare the clinical efficacy of telbivudine(LDT)and entecavir(ETV)in the treatment of patients with HBe Ag positive chronic hepatitis B(CHB)Methods A total of 82 patients with HBe Ag positive CHB admitted to our hospital from August 2014 to August 2016 were enrolled.According to the treatment method,these patients regularly review the relevant indicators in our hospital every 3 months.They were divided into LDT group(observation group,52 cases)and ETV group(control group,30 cases).Observation group :LDT 600 mg,1 time / d;control group: ETV 0.5 mg,1 time / d.At the treatment of 12 w,24w,48 w,72w,96 w,the dynamic changes of ALT recurrence rate,HBs Ag negative conversion rate and the dynamic change of HBs Ag quantification.,HBe Ag negative conversion rate and HBe Ag quantitative dynamic change,HBe Ag/anti-HBe were observed.The conversion rate and HBV-DNA were lower than the detection lower limit rate and the dynamic change of HBV-DNA quantification.RESULTS After treatment,the ALT recurrence rate at 12 w,24w,48 w,72w,96 w was not significantly different between the two groups(P>0.05).There was no significant difference in the HBs Ag negative conversion rate and the changes at each time point.(P>0.05);Also,there was no significant difference in HBe Ag conversion rate between the two groups after treatment for 12 w,24w,48w(P>0.05).Afterwards,the HBe Ag conversion rate of the observation group was 34.6%(18/52),and the conversion rate of the control group was 16.7%(5/30).The two groups were statistically significant by chi-square test(P<0.05).The HBe Ag conversion rate of serum was significantly higher than that of the control group.At 48 w,72w,96 w,the decrease of HBe Ag in the observation group was significantly higher than that of the control group(P<0.05).There was no significant difference between the two groups in the HBV-DNA below the detection limit rate and the dynamic changes of HBV-DN A at each time point(P>0.05).No significant adverse effects were observed in the two groups during the course of treatment.Conclusion Compared with the control group,the observation group has better treatment effect on HBe Ag positive CHB patients,higher HBe Ag conversion rate and more obvious HBe Ag value decrease.Both groups have better safety.